loader from loading.io

Streamlining the Process for Accessing Medical Marijuana Cards with Aspen Noonan Elevate Holistics

Empowered Patient Podcast

Release Date: 09/04/2025

Using AI in Drug Development to Protect Brain Enzyme Linked  to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT show art Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT

Empowered Patient Podcast

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...

info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics show art Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics

Empowered Patient Podcast

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...

info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals TRANSCRIPT show art Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals TRANSCRIPT

Empowered Patient Podcast

Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...

info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals show art Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals

Empowered Patient Podcast

Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...

info_outline
Leveraging Non-Dilutive Funding for Ultra-Rare Disease Development with Dr. George Magrath Opus Genetics TRANSCRIPT show art Leveraging Non-Dilutive Funding for Ultra-Rare Disease Development with Dr. George Magrath Opus Genetics TRANSCRIPT

Empowered Patient Podcast

Dr. George Magrath, CEO of Opus Genetics, discusses the company's experience in obtaining non-dilutive funding for its ultra-rare inherited retinal disease program. He highlights the challenges and advantages of this funding source, as well as the importance of establishing relationships with patient advocacy groups and foundations to mitigate risk and increase their attractiveness to traditional investors. The drive for non-dilutive funding for ultra-rare diseases is expected to become increasingly important in helping to get drugs to clinical trials. George explains, "Opus Genetics is a...

info_outline
Leveraging Non-Dilutive Funding for Ultra-Rare Disease Development with Dr. George Magrath Opus Genetics show art Leveraging Non-Dilutive Funding for Ultra-Rare Disease Development with Dr. George Magrath Opus Genetics

Empowered Patient Podcast

Dr. George Magrath, CEO of Opus Genetics, discusses the company's experience in obtaining non-dilutive funding for its ultra-rare inherited retinal disease program. He highlights the challenges and advantages of this funding source, as well as the importance of establishing relationships with patient advocacy groups and foundations to mitigate risk and increase their attractiveness to traditional investors. The drive for non-dilutive funding for ultra-rare diseases is expected to become increasingly important in helping to get drugs to clinical trials. George explains, "Opus Genetics is a...

info_outline
AI Revolutionizing Drug Development Regulatory Documentation and FDA Submission with Lindsay Mateo Weave TRANSCRIPT show art AI Revolutionizing Drug Development Regulatory Documentation and FDA Submission with Lindsay Mateo Weave TRANSCRIPT

Empowered Patient Podcast

Lindsay Mateo is the Chief Commercial Officer at Weave. This company has developed a platform to automate and streamline the regulatory documentation process for FDA submission for pharmaceutical and biotech companies.  The regulatory lifecycle for drug development currently involves data from various sources in digital and paper formats. Weave Bio's tools are designed to automate and streamline administrative aspects of the regulatory process and create a living digital record of the development of the drug, which supports collaboration and saves time. Lindsay explains, "I look at the...

info_outline
AI Revolutionizing Drug Development Regulatory Documentation and FDA Submission with Lindsay Mateo Weave show art AI Revolutionizing Drug Development Regulatory Documentation and FDA Submission with Lindsay Mateo Weave

Empowered Patient Podcast

Lindsay Mateo is the Chief Commercial Officer at Weave. This company has developed a platform to automate and streamline the regulatory documentation process for FDA submission for pharmaceutical and biotech companies.  The regulatory lifecycle for drug development currently involves data from various sources in digital and paper formats. Weave Bio's tools are designed to automate and streamline administrative aspects of the regulatory process and create a living digital record of the development of the drug, which supports collaboration and saves time. Lindsay explains, "I look at the...

info_outline
Streamlining the Process for Accessing Medical Marijuana Cards with Aspen Noonan Elevate Holistics TRANSCRIPT show art Streamlining the Process for Accessing Medical Marijuana Cards with Aspen Noonan Elevate Holistics TRANSCRIPT

Empowered Patient Podcast

Aspen Noonan, CEO of Elevate Holistics, a company that helps patients obtain medical marijuana cards through a telehealth consultation with licensed doctors. The qualifications for obtaining a medical marijuana card vary by state, and Elevate Holistics helps patients navigate the regulatory landscape. Many doctors are hesitant to recommend cannabis due to the federal illegality and restrictions from employers, and Elevate Holistics is filling the gaps by connecting patients looking for alternative treatments for conditions such as anxiety, depression, PTSD, and chronic pain. Aspen explains,...

info_outline
Streamlining the Process for Accessing Medical Marijuana Cards with Aspen Noonan Elevate Holistics show art Streamlining the Process for Accessing Medical Marijuana Cards with Aspen Noonan Elevate Holistics

Empowered Patient Podcast

Aspen Noonan, CEO of Elevate Holistics, a company that helps patients obtain medical marijuana cards through a telehealth consultation with licensed doctors. The qualifications for obtaining a medical marijuana card vary by state, and Elevate Holistics helps patients navigate the regulatory landscape. Many doctors are hesitant to recommend cannabis due to the federal illegality and restrictions from employers, and Elevate Holistics is filling the gaps by connecting patients looking for alternative treatments for conditions such as anxiety, depression, PTSD, and chronic pain. Aspen explains,...

info_outline
 
More Episodes

Aspen Noonan, CEO of Elevate Holistics, a company that helps patients obtain medical marijuana cards through a telehealth consultation with licensed doctors. The qualifications for obtaining a medical marijuana card vary by state, and Elevate Holistics helps patients navigate the regulatory landscape. Many doctors are hesitant to recommend cannabis due to the federal illegality and restrictions from employers, and Elevate Holistics is filling the gaps by connecting patients looking for alternative treatments for conditions such as anxiety, depression, PTSD, and chronic pain.

Aspen explains, "We are a one-stop shop for getting your online medical marijuana card. We connect doctors with patients 100% online in over 18 states to go through the process, which basically means book your appointment, fill out forms, join a video chat, call, and check for your emails because it's a hands-off experience. We really help people. I say A to Z, we don't just see you and get out. We ensure that your state application is filed correctly, so you ca your medical card at the end of the day."  

"You have every right to ask your primary care provider for a medical marijuana recommendation. The problem is, and the reason we started, is that a lot of doctors do not want to sign their name next to something that says cannabis. They aren't allowed to go through their clinics. Let's say they work at a hospital, they work at a big organization, and they're not allowed to attach their name to the cannabis industry. And so that's where we come in and just take patients, take a provider, put them together." 

#ElevateHolistics #Marijuana #Cannabis #MedialMarijuana #MedicalMarijuanaCard

elevate-holistics.com

Download the transcript here 

Elevate